Posted by Michael Wonder on 13 Jan 2023
Takeda’s Exkivity (mobocertinib) receives approval from the NMPA of China, becoming the first and only therapy available for patients with EGFR exon20 insertion positive NSCLC
12 January 2023 - Exkivity is the first category-1 innovative drug approved for Takeda China following a Phase 2 global pivotal study.
Takeda today announced that Exkivity (mobocertinib) has been approved by the NMPA of China for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
